Allison C Sharrow1, Brandy Perkins2, Michael I Collector3, Wayne Yu4, Brian W Simons5, Richard J Jones6. 1. Department of Pathology, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. Electronic address: acsharrow@gmail.com. 2. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. Electronic address: bperkin6@jhmi.edu. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. Electronic address: Wyu8@jhmi.edu. 5. Departments of Pathology and Molecular & Comparative Pathobiology, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. Electronic address: bsimons3@jhmi.edu. 6. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St., Baltimore, MD, USA. Electronic address: rjjones@jhmi.edu.
Abstract
OBJECTIVE: The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDH(high)) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDH(high) cells in ovarian cancer. METHODS: We compared ALDH(high) to ALDH(low) cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous rat endometrioid carcinoma, and the human SKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. RESULTS: ALDH(high) cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDH(high) cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDH(high) cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. CONCLUSIONS: Based on functional characterization, ALDH(high) ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.
OBJECTIVE: The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDH(high)) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDH(high) cells in ovarian cancer. METHODS: We compared ALDH(high) to ALDH(low) cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous ratendometrioid carcinoma, and the humanSKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. RESULTS:ALDH(high) cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDH(high) cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDH(high) cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. CONCLUSIONS: Based on functional characterization, ALDH(high) ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.
Authors: Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman Journal: Cell Date: 2009-07-23 Impact factor: 41.582
Authors: Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2012-03-26 Impact factor: 11.205
Authors: Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; N V Rajeshkumar; Xiaobing He; Michael Goggins; Christine Iacobuzio-Donahue; David M Berman; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui Journal: J Natl Cancer Inst Date: 2010-02-17 Impact factor: 13.506
Authors: Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess Journal: J Ovarian Res Date: 2010-03-31 Impact factor: 4.234
Authors: Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Vinod Vathipadiekal; Deepa Saxena; Samuel C Mok; Peter V Hauschka; Laurent Ozbun; Michael J Birrer Journal: PLoS One Date: 2012-01-17 Impact factor: 3.240
Authors: Bin Chang; Guangzhi Liu; Fengxia Xue; Daniel G Rosen; Lianchun Xiao; Xuemei Wang; Jinsong Liu Journal: Mod Pathol Date: 2009-03-27 Impact factor: 7.842
Authors: Shreya Raghavan; Pooja Mehta; Maria R Ward; Michael E Bregenzer; Elyse M A Fleck; Lijun Tan; Karen McLean; Ronald J Buckanovich; Geeta Mehta Journal: Clin Cancer Res Date: 2017-08-16 Impact factor: 12.531
Authors: Eric N Horst; Michael E Bregenzer; Pooja Mehta; Catherine S Snyder; Taylor Repetto; Yang Yang-Hartwich; Geeta Mehta Journal: Acta Biomater Date: 2021-04-30 Impact factor: 10.633
Authors: Anna Pagotto; Giorgia Pilotto; Elena Laura Mazzoldi; Maria Ornella Nicoletto; Simona Frezzini; Anna Pastò; Alberto Amadori Journal: Cell Death Dis Date: 2017-07-20 Impact factor: 8.469